article thumbnail

Tenax Therapeutics Announces New U.S. Patent Covering the Use of Levosimendan in Pulmonary Hypertension with Heart Failure with Preserved Ejection Fraction (PH-HFpEF)

DAIC

We are committed to protecting the future commercial value of our innovative PH-HFpEF treatment,” said Chris Giordano , President & Chief Executive Officer of Tenax Therapeutics. Getty Images milla1cf Mon, 05/06/2024 - 10:48 May 6, 2024 — Tenax Therapeutics, Inc. ,

article thumbnail

Emerging technology : An Intelligent vacuum thrombo-aspiration system for Acute pulmonary embolism

Dr. S. Venkatesan MD

A new Intelligent thrombo-suction catheter system , is being introduced for treatment of acute pulmonary embolism.This device regulates the force with which thrombus is sucked , with less injury and bleeding and better outcomes. They have become a Integral tool kit in peripheral arterial, venous and also pulmonary thrombosis.We

article thumbnail

Edwards Lifesciences Expands Structural Heart Portfolio With Acquisitions of JenaValve and Endotronix

DAIC

mtaschetta-millane Mon, 07/29/2024 - 09:02 July 29, 2024 — Edwards Lifesciences announced investments that reflect the company’s deep commitment to advancing patient care through structural heart innovation, addressing large unmet patient needs and supporting sustainable long-term growth. JenaValve presented positive results of its U.S.

article thumbnail

Optimizing percutaneous pulmonary valve implantation with patient-specific 3D-printed pulmonary artery models and hemodynamic assessment

Frontiers in Cardiovascular Medicine

Background Percutaneous pulmonary valve implantation (PPVI) has emerged as a less invasive alternative for treating severe pulmonary regurgitation after tetralogy of Fallot (TOF) repair in patients with a native right ventricular outflow tract (RVOT).

article thumbnail

CardioFocus to Present Data Supporting Next Generation Pulsed Field Ablation Systems at Heart Rhythm 2024

DAIC

CardioFocus will feature its portfolio of innovative ablation systems which optimize lesion creation via confirmed tissue contact and sophisticated energy delivery. Our pursuit of innovation towards clinically meaningful ablation systems is driven by a focus on patient outcomes" said CardioFocus CEO Steve Ogilvie. "At

article thumbnail

Radiofrequency catheter ablation for re-do procedure after single-shot pulmonary vein isolation with pulsed field ablation for paroxysmal atrial fibrillation: case report

Frontiers in Cardiovascular Medicine

BackgroundCatheter ablation is frequently used to manage recurrent atrial fibrillation (AF) resistant to drug therapy, with pulmonary vein isolation (PVI) as a key tactic. The reconnection of pulmonary veins was discovered primarily in the anterior region of the right superior PV and the superior portion of the left superior PV.

article thumbnail

Inhaled NO at a crossroads in cardiac surgery: current need to improve mechanistic understanding, clinical trial design and scientific evidence

Frontiers in Cardiovascular Medicine

Inhaled NO has the unique ability to exert its vasodilatory effects in the pulmonary vasculature without any hypotensive side-effects in the systemic circulation. We will move on to the popular use of inhaled NO and will talk about the evidence base of the use of this selective pulmonary vasodilator.